Undersökning av potentiella målstyrda behandlingar vid bukaortaaneurysm

Title [sv]

Abstract [sv]

Bakgrund:Cardiovascular disease, including abdominal aortic aneurysm (AAA), is anenormous health care burden and ruptured AAA account for approximately 200,000 of annual deaths. AAA is an inflammatory disease and despite long-term anti-inflammatory and lipid lowering treatment due to other underlying vascular disease the majority of AAA patients have, these drugs neither prevent nor inhibit aneurysm disease. Not a single drug treatment for aneurysm exist. However, our pre-clinical experiments indicate that glycolysis/metabolism could be an important target. This indicates that more specific immune cell targeting is required to inhibit aneurysm development.Målsättning:To be able to find new therapeutic preventive strategies the molecular mechanisms behind the disease and drug targets needs to be elucidated in more detail. Based on previous studies me and my team have identified several key factors that could be targeted by certain drugs. The main aim is to clarify pathophysiological and molecular mechanisms behind AAA disease and to find novel treatment strategies.Arbetsplan:Human samples, cell and animal models of aneurysm disease will be used to target novel pathways, immune cell activation and vascular remodelling via transcriptional regulation and by targeting glycolysis using the GLP-1 agonist semaglutide.Betydelse:The importance of this research is to increase the knowledge of pathogenesis of AAA so that standardized surgery can be replaced by individual risk -adapted medication resulting in reduced mortality and fewer complications leading to better quality of life.

Abstract [en]

Bakgrund:Cardiovascular disease, including abdominal aortic aneurysm (AAA), is anenormous health care burden and ruptured AAA account for approximately 200,000 of annual deaths. AAA is an inflammatory disease and despite long-term anti-inflammatory and lipid lowering treatment due to other underlying vascular disease the majority of AAA patients have, these drugs neither prevent nor inhibit aneurysm disease. Not a single drug treatment for aneurysm exist. However, our pre-clinical experiments indicate that glycolysis/metabolism could be an important target. This indicates that more specific immune cell targeting is required to inhibit aneurysm development.Målsättning:To be able to find new therapeutic preventive strategies the molecular mechanisms behind the disease and drug targets needs to be elucidated in more detail. Based on previous studies me and my team have identified several key factors that could be targeted by certain drugs. The main aim is to clarify pathophysiological and molecular mechanisms behind AAA disease and to find novel treatment strategies.Arbetsplan:Human samples, cell and animal models of aneurysm disease will be used to target novel pathways, immune cell activation and vascular remodelling via transcriptional regulation and by targeting glycolysis using the GLP-1 agonist semaglutide.Betydelse:The importance of this research is to increase the knowledge of pathogenesis of AAA so that standardized surgery can be replaced by individual risk -adapted medication resulting in reduced mortality and fewer complications leading to better quality of life.

Umeå University's logo

Project

Project type/Form of grant

Uppsala University

Uppsala University

Uppsala University

Coordinating organisation

Funder

Hjärt-Lungfonden

Period

Identifiers

Search in DiVA

Search outside of DiVA